Evidence map›Paper›PMID 37634682›Full record

ArticleBone2023

Contributions of increased osteopontin and hypophosphatemia to dentoalveolar defects in osteomalacic Hyp mice.

Fatma F Mohamed, Betty Hoac, Aonjittra Phanrungsuwan, Michelle H Tan, Priscila Alves Giovani, Sana Ghiba, Monzur Murshed, Brian L Foster, Marc D McKee

Open access · greenAbstract read
In one paragraph

Article in Bone, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Fatma F MohamedDivision of Biosciences, College of Dentistry, The Ohio State University, Columbus, OH, USA.
Betty HoacFaculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada.
Aonjittra PhanrungsuwanDivision of Biosciences, College of Dentistry, The Ohio State University, Columbus, OH, USA.
Michelle H TanDivision of Biosciences, College of Dentistry, The Ohio State University, Columbus, OH, USA.
Priscila Alves GiovaniCampinas State University, School of Dentistry, Piracicaba, São Paulo, Brazil.
Sana GhibaDivision of Biosciences, College of Dentistry, The Ohio State University, Columbus, OH, USA.
Monzur MurshedFaculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada; Department of Medicine, Faculty of Medicine, McGill University, Montreal, QC, Canada; Shriners Hospital for Children, Montreal, QC, Canada.
Brian L FosterDivision of Biosciences, College of Dentistry, The Ohio State University, Columbus, OH, USA. Electronic address: foster.1004@osu.edu.
Marc D McKeeFaculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada; Department of Anatomy and Cell Biology, School of Biomedical Sciences, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada. Electronic address: marc.mckee@mcgill.ca.
The Ohio State University · USMcGill University Health Centre · CAUniversidade Estadual de Campinas (UNICAMP) · BR

Funding

Identifying Novel Mechanisms for Dentoalveolar Mineralization Defects in X-linked HypophosphatemiaR01DE032334 · NIDCR · OHIO STATE UNIVERSITY · PI Brian Lee Foster · 2022 to 2026
$2.5M
NIDCR NIH HHS R01 DE032334
6 · The paper itself

Abstract

X-linked hypophosphatemia (XLH) is an inherited disorder caused by inactivating mutations in the PHEX gene leading to renal phosphate wasting, rickets and osteomalacia. XLH is also associated with dentoalveolar mineralization defects in tooth enamel, dentin and cementum, and in alveolar bone, which lead to an increased prevalence of dental abscesses, periodontal disease and tooth loss. Genetic mouse experiments, and deficiencies in XLH patient therapies where treatments do not fully ameliorate mineralization defects, suggest that other pathogenic mechanisms may exist in XLH. The mineralization-inhibiting, secreted extracellular matrix phosphoprotein osteopontin (OPN, gene Spp1) is a substrate for the PHEX enzyme whereby extensive and inactivating degradation of inhibitory OPN by PHEX facilitates mineralization. Conversely, excess OPN accumulation in skeletal and dental tissues - for example in XLH where inactivating mutations in the PHEX gene limit degradation of inhibitory OPN, or as occurs in Fgf23-null mice - contributes to mineralization defects. We hypothesized that Spp1/OPN ablation in Hyp mice (a mouse model for XLH) would reduce dentoalveolar mineralization defects. Immunostaining revealed increased OPN in Hyp vs. wild-type (WT) alveolar bone, particularly in osteocyte lacunocanalicular networks where Hyp mice have characteristic hypomineralized peri-osteocytic lesions (POLs). Micro-computed tomography and histology showed that ablation of Spp1 in Hyp mice (Hyp;Spp1

Indexed as

Bone DiseasesCalcinosisFamilial Hypophosphatemic RicketsHypophosphatemiaAnimalsMiceMice, KnockoutOsteopontinPhosphatesX-Ray MicrotomographyOsteopontinPhosphatesBoneOsteomalaciaOsteopontinPeriodontiumTeethX-linked hypophosphatemia

Identifiers

PMID37634682
PMCPMC10529969
OpenAlexW4386158422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.